Roche

News

US/EU regulators start review of Biogen's high-dose Spinraza

Biogen's new high-dose version of SMA drug Spinraza has started regulatory reviews - but can it help return the drug to growth?

News

Roche licenses Innovent ADC that could challenge Amgen drug

Roche licenses rights to a DLL3-targeted ADC from China's Innovent, hoping to bring a competitor to Amgen's lung cancer therapy Imdelltra to market.

News

Roche's Parkinson's hope fails second clinical trial

Roche and Prothena's alpha-synuclein-targeting prasinezumab for Parkinson's fails again, leaving them sifting through the data for efficacy signals.

News

Roche buys off-the-shelf CAR-T player Poseida for $1bn

Roche has upgraded its partnership with off-the-shelf CAR-T therapy specialist Poseida to a $1 billion-plus takeover bid

News

Roche trial confirms Vabysmo efficacy in minorities

A study has shown that Roche's diabetic macular oedema (DME) therapy Vabysmo is effective in patients who identify as African American, Black, Hispanic and Latino, plugging a gap in the dat

News

NICE backs first targeted therapy for ALK+ lung cancer

Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.

US/EU regulators start review of Biogen's high-dose Spinraza

Roche licenses Innovent ADC that could challenge Amgen drug

Roche's Parkinson's hope fails second clinical trial

Roche buys off-the-shelf CAR-T player Poseida for $1bn

Roche trial confirms Vabysmo efficacy in minorities

NICE backs first targeted therapy for ALK+ lung cancer

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Roche

Editor's Picks